

AMENDMENT

In the Claims:

Please amend claims 26 and 30 and add new claims 38-43 as indicated below:

26. (Amended) A method of palliating an allergic reaction in a mammalian subject, comprising the steps of:

identifying a mammalian subject in need of treatment for an allergic reaction that is characterized by eosinophil accumulation, and

administering to said mammalian subject a composition comprising an MDC antagonist compound in an amount effective to palliate the allergic reaction.

30. (Twice Amended) A method according to claim 26 wherein the MDC antagonist compound is selected from the group consisting of:

- (a) an antibody that specifically binds a vertebrate MDC polypeptide;
- (b) a polypeptide that specifically binds a vertebrate MDC polypeptide and comprises an antigen-binding fragment of an anti-MDC antibody;
- (c) a polypeptide comprising the C-C chemokine receptor 4 (CCR4) amino acid sequence set forth in SEQ ID NO: 34 or comprising a continuous fragment thereof that specifically binds MDC; and
- (d) combinations of (a)-(c).

38. (New) The method according to claim 26 wherein the MDC antagonist compound is a monoclonal antibody selected from the group consisting of 191D, 252Y and 252Z.

39. (New) The method according to claim 26, wherein the MDC antagonist compound is a polypeptide that specifically binds a vertebrate MDC polypeptide and comprises an antigen-binding fragment of an anti-MDC antibody.

40. (New) The method according to claim 26 wherein the MDC antagonist compound comprises a polypeptide selected from the group consisting of N-terminal deletion polypeptide mutants of amino acids 1-69 of SEQ ID NO: 2 in which 1-11 residues have been deleted, a polypeptide having the amino acid sequence of SEQ ID NO: 30 ("MDC (n+1)"), N-terminal addition polypeptide mutants of amino acids 1-69 of SEQ ID NO: 2 in which at least one amino acid residue is added, a polypeptide having the amino acid sequence of SEQ ID NO: 31 ("MDC-yl"), a polypeptide having the amino acid sequence of SEQ ID NO: 32 ("MDC-eyfy"), and MDC Δ Pro2 polypeptides.

41. (New) The method according to claim 26 wherein the MDC antagonist compound comprises a polypeptide having the amino acid sequence of SEQ ID NO: 25.

42. (New) A method of palliating an allergic reaction in a mammalian subject, comprising the steps of:

identifying a mammalian subject in need of treatment for an allergic reaction that is characterized by eosinophil accumulation, and

administering to said mammalian subject a composition comprising a TARC antagonist compound in an amount effective to palliate the allergic reaction.

43. (New) A method according to claim 42 wherein the TARC antagonist compound is selected from the group consisting of:

(a) an antibody that specifically binds a vertebrate TARC polypeptide;

(b) a polypeptide that specifically binds a vertebrate TARC polypeptide and comprises an antigen-binding fragment of an anti-TARC antibody;

(c) a polypeptide comprising the C-C chemokine receptor 4 (CCR4) amino acid sequence set forth in SEQ ID NO: 34 or comprising a continuous fragment thereof that specifically binds TARC; and

(d) combinations of (a)-(c).